Category: Pα+ - Psychedelic Alpha

Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.

Read more about the article Real-World Data Reveals Variability in Access to, and Use of, Spravato

Real-World Data Reveals Variability in Access to, and Use of, Spravato

Post published:September 13, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase I

Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase I

Post published:September 9, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Exclusive: David Hough on Lykos’ Path to Resubmission

Exclusive: David Hough on Lykos’ Path to Resubmission

Post published:September 4, 2024
Post category:Interviews Pα+

Read more about the article Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine Crackdown

Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine Crackdown

Post published:August 30, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)

Post published:August 28, 2024
Post category:Analysis News Pα+

Read more about the article What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 1)

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 1)

Post published:August 22, 2024
Post category:Analysis News Pα+

Read more about the article Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran, Doblin Resigns Board

Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran, Doblin Resigns Board

Post published:August 15, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase 2 for DMT and R-MDMA Candidates; Compass’ Phase 3 Readout Timeline; European Psychiatrists Remain Open to Psychedelics

Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase 2 for DMT and R-MDMA Candidates; Compass’ Phase 3 Readout Timeline; European Psychiatrists Remain Open to Psychedelics

Post published:August 15, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Lykos Plots FDA Appeal: Reeling from CRL and Journal Article Retractions, MDMA Developer Hopes to Change Your Mind

Lykos Plots FDA Appeal: Reeling from CRL and Journal Article Retractions, MDMA Developer Hopes to Change Your Mind

Post published:August 13, 2024
Post category:Analysis News Pα+

Read more about the article Psychedelic Funding Update: Q2 2024

Psychedelic Funding Update: Q2 2024

Post published:August 1, 2024
Post category:Analysis Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.